Treatment of fibrostenotic and fistulizing crohn's disease

Digestion

Volumn 86, Issue SUPPL. 1, 2012, Pages 23-27

  Schoepfer, Alain M ^a   Safroneeva, Ekaterina ^b   Vavricka, Stephan R ^c,d   Peyrin Biroulet, Laurent ^f   Mottet, Christian ^a,e  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Division of Gastroenterology and Hepatology   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Division of Gastroenterology and Hepatology   (Switzerland)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Crohn's disease; Perianal fistulas; Stricture

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; STEROID; TACROLIMUS;

ANTIBIOTIC THERAPY; ANUS FISTULA; ARTICLE; BALLOON DILATATION; CLINICAL ASSESSMENT; CROHN DISEASE; DISEASE COURSE; EDEMA; FIBROSTENOTIC CROHN DISEASE; HUMAN; ILEOSTOMY; IMMUNOMODULATION; INTESTINE STENOSIS; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MORBIDITY; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM RESECTION; RELAPSE; REOPERATION; SHORT BOWEL SYNDROME; SURGICAL RISK; TASTE DISORDER; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; DILATATION; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL FISTULA; INTESTINAL OBSTRUCTION;

EID: 84867529858     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000341961     Document Type: Article

References (33)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenter-ology 2011; 140:1785-1794.
2. Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of fis-tulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-880.
3. Hellers G, Bergstrand O, Ewerth S, Holm-ström B: Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980; 21:525-527.
4. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB: AGA technical review on peri-anal Crohn's disease. Gastroenterology 2003; 125: 1508-1530.
5. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos A, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohn Colitis 2010; 4:63-101.
6. Irvine EJ: Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20:27-32.
7. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWood KL, Schaibl TF, van Deventer SJ: Infliximab for the treatment of fistulas with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
8. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, Sutherland LR: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterolog y 2002; 122: 512-530.
9. Pascua M, Su C, Lewis JD, Brensinger C, Lich tenstein GR: Meta-analysis: factor predicting post-operative recurrence with placebo therapy in patients with Crohn's disease. Aliment Pharmacol Ther 2008; 28: 545-556.
10. Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC: Inf liximab treatment for symptomtic Crohn's disease strictures. Aliment Pharmacol Ther 2009; 29: 279-285.
11. Louis E, Boverie J, Dewit O, Baert F, De Vos M, D'Haens G, Belgian IBD Research Group: Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007; 70: 15-19.
12. Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M: Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease. Z Gastroenterol 2003; 41:11-17.
13. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ: Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101:1030-1038.
14. Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S: Systematic Review: Endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther 2007;26:1457-1464.
15. Dietz DW, Laureti S, Strong SA, Hull TL, Church J, Remzi FJ, Lavery IC, Fazio VW: Safety and long-term efficacy of stricture-plasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surg 2001; 192: 330-338.
16. Fearnhead NS, Chowdhury R, Box B, George BD, Jewell DP, Mortensen NJ: Long-term follow-up of strictureplasty for Crohn's disease. Br J Surg 2006; 93: 475-482.
17. Fazio VW, Marchetti F, Church M, Gold-blum JR, Lavery C, Hull TL, Milsom JW, Strong SA, Oakley JR, Secic M: Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized control led tria l. Ann Surg 1996; 224: 563-571.
18. Bernstein LH, Frank MS, Brandt LJ, Boley SJ: Healing of perineal Crohn's disease with metronidazole. Gastroenterolog y 1980; 79: 357-365.
19. Brandt LJ, Bernstein LH, Boley SJ, Frank MS: Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83:383-387.
20. Turunen U, Farkkila M, Seppala K: Long-term treatment of peri-anal or fistulous Crohn's disease with ciprofloxacin. Scand J Gastroenterol 1989; 24:(suppl 48):144.
21. Wolf J: Ciprofloxacin may be useful in Crohn's disease. Gastroenterology 1990; 98:A212.
22. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers J: Clinical and endosonographic effect of ciprof loxacin on the treatment of peri-anal fistulae in Crohn's disease with inflixi-mab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 1329-36.
23. Pearson CD, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 122: 132-142.
24. Mahadevan U, Marion JF, Present DH: Fis-tu la re sponse to methot rexate i n Croh n's disease: a case series. Aliment Pharmacol Ther 2003; 18: 1003-1008.
25. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
26. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulazing Crohn's disease. N Engl J Med 2004; 350: 876-885.
27. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schrei-ber S, Byczkowski D, Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM Trial. Gastro-enterology 2007; 132: 52-65.
28. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF: Adalimumab for the treatment offistulas in patients with Crohn's disease. Gut 2009; 5:940-948.
29. Sandborn WJ, Feagan BG, Stoinov S, Honi-ball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
30. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomson O, Hanauer SB, McColm J, Bloomfield R, Sandbron WJ: Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250.
31. Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P, Swiss IBDnet: Inflamm Bowel Dis 2011; 17: 1530-1539.
32. Ng SC, Arebi N, Kamm MA: Medium-term results of oral tacrolimus for treatment of refractory inflammatory bowel disease. Inf lamm Bowel Dis 2007; 13: 129-134.
33. Sandborn WJ: A critical review of cyclospo-rine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48-63.